Digoxin - a therapeutic agent and mechanistic probe: review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin
- PMID: 21083191
- DOI: 10.4155/bio.09.14
Digoxin - a therapeutic agent and mechanistic probe: review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin
Abstract
Digoxin is an important therapeutic agent for the treatment of congestive cardiac failure. In spite of its narrow therapeutic index, digoxin has been used extensively by the medical community and, lately, the use of digoxin as a mechanistic probe for p-glycoprotein transporter activity has increased. This review describes recent trends in the bioanalysis of digoxin, where scores of liquid chromatographic-mass spectrometric assays have been successfully employed to measure digoxin in preclinical, clinical and mechanistic studies. It provides various considerations such as internal standard selection, extraction schemes, matrix effect, selectivity evaluation and optimization of mass spectral conditions, for example, to enable the development of sound bioanalytical methods for digoxin. Some recent updates with regard to clinical pharmacology, absorption and disposition aspects of digoxin have been included. Overall, liquid chromatographic-mass spectrometric assays represent an important tool for many future preclinical, clinical and mechanistic probe studies that would probe digoxin with or without other coadministered substrates.
Similar articles
-
Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview.Biomed Chromatogr. 2011 Jan;25(1-2):218-37. doi: 10.1002/bmc.1522. Epub 2010 Nov 5. Biomed Chromatogr. 2011. PMID: 21204112 Review.
-
Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 15;869(1-2):126-32. doi: 10.1016/j.jchromb.2008.05.026. Epub 2008 May 22. J Chromatogr B Analyt Technol Biomed Life Sci. 2008. PMID: 18515196
-
Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen.Rapid Commun Mass Spectrom. 2011 May 15;25(9):1231-40. doi: 10.1002/rcm.4984. Rapid Commun Mass Spectrom. 2011. PMID: 21488121
-
Absence of an interaction between tigecycline and digoxin in healthy men.Pharmacotherapy. 2007 Jun;27(6):835-44. doi: 10.1592/phco.27.6.835. Pharmacotherapy. 2007. PMID: 17542766 Clinical Trial.
-
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.Pharmacol Res. 1999 Oct;40(4):301-6. doi: 10.1006/phrs.1999.0535. Pharmacol Res. 1999. PMID: 10527640 Review.
Cited by
-
Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS.Int J Mol Sci. 2023 Jan 17;24(3):1848. doi: 10.3390/ijms24031848. Int J Mol Sci. 2023. PMID: 36768172 Free PMC article.
-
Development of a new ultra-high-performance liquid chromatography-tandem mass spectrometry method for the determination of digoxin and digitoxin in plasma: Comparison with a clinical immunoassay.Electrophoresis. 2022 May;43(9-10):1019-1026. doi: 10.1002/elps.202100290. Epub 2022 Feb 17. Electrophoresis. 2022. PMID: 35132652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical